Takeda Pharmaceutical Agrees to $2.4 Billion Settlement Resolving Thousands of Bladder Cancer Cases

Takeda Pharmaceutical is a Japanese company that has been defending as many as 9,000 lawsuits or claims for individuals who were taking the medication Actos, which is a Type 2 diabetes drug. Takeda’s United States’ headquarters is located in Deerfield, Ill.

The filed complaints include 4,000 in Cook County, Ill., another 4,000 filed in Louisiana and about 800 filed in Florida. There are still other cases filed in federal court in the Western District of Louisiana; these are part of the Multidistrict Litigation (MDL). In one of those cases, tried to a jury in 2014, the verdict against Takeda and Eli Lilly was for $9 billion, which set a record. In that case Takeda was found to have destroyed evidence about Actos and its link to bladder cancer. It was also revealed that Takeda’s former employees and some top executives in the U.S. and Japan deleted files that if considered would have had negative impact. That verdict amount was later reduced by the presiding judge and is on the appeal filed by Takeda. That case as consolidated is titled In re Actos (Pioglitazone) Products Liability Litigation, 11- md-02299, U.S. District Court, Western District of Louisiana (Lafayette).

According to reports, the diabetes drug Actos produced $16 billion in sales since it went on the market for public use in 1999. In June 2011, the United States Food and Drug Administration (USDA) issued a written warning about the possible risk of bladder cancer for those patients who were taking Actos for a year or longer. In August 2011, the FDA issued a new warning about Actos stating that people taking Actos “may be an increased risk for developing bladder cancer.”

Among the complaints filed against Takeda is one of Kreisman Law Offices’ clients who had been taking Actos for more than one year and developed early stages of bladder cancer. Our client will be in the group of cases being settled. This settlement is one of the largest of its kind. Takeda is Asia’s largest pharmaceutical producer.

The way this case’s settlement proceeds will be apportioned is dependent on pre-existing risks, like smoking, exposures to dangerous chemicals or toxins that are associated with bladder cancer and the amount of the Actos dosage the patient was taking.

There will be a grid settlement matrix developed, which has been used before in other complex pharmaceutical settlements. The patients/plaintiffs who have been victimized with the more severe metastatic spread of cancer or who have unfortunately already passed away will receive a more substantial settlement amount than others who have been less affected. It is believed that the average settlement amount will range in the area of $275,000.

The class of plaintiffs in these cases includes those who were taking Actos before December 2011 and have been diagnosed with bladder cancer since that time.

Kreisman Law Offices has been handling product liability cases, pharmaceutical defect cases, wrongful death cases and catastrophic injury cases for individuals and families who have been harmed, injured or died as a result of the carelessness or negligence of another for more than 38 years in and around Chicago, Cook County and its surrounding areas, including Schiller Park, Tinley Park, Glenview, Northfield, Evergreen Park, Schaumburg, Orland Park, Palos Hills, Chicago (Roscoe Village, West Loop, Lincoln Square, Little Village, Little Italy, Chinatown), Waukegan, Elgin, Aurora, Warrenville, Wheaton, St. Charles and Lake Bluff, Ill.

Related blog posts:

Actos Trials Under Way in Illinois; Juries in California and Maryland Reach Verdicts

$90 Million Settlement Paid by Pharmaceutical Company For Its Unfair and Deceptive Promotion of Diabetes Drug

Illinois Jury Verdict for 2.2 Million in First Humira Infection Case